Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trialMichael R. Migden, Reinhard Dummer, Manisha Mone et al.|The Lancet Oncology|2015Cited by 432
Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT studyJohn T. Lear, Reinhard Dummer, Michael R. Migden et al.|Journal of the European Academy of Dermatology and Venereology|2017Cited by 192
The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinomaReinhard Dummer, Michael R. Migden, Alexander Guminski et al.|Journal of the American Academy of Dermatology|2016Cited by 163
Randomized, double-blind study of sonidegib (LDE225) in patients (pts) with locally advanced (La) or metastatic (m) basal-cell carcinoma (BCC)Michael R. Migden, Reinhard Dummer, Alexander Guminski et al.|Journal of Clinical Oncology|2014Cited by 12
Efficacy and safety of sonidegib in patients (pts) with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC): BOLT 30-month analysis.Reinhard Dummer, John T. Lear, Michael R. Migden et al.|Journal of Clinical Oncology|2016Cited by 2